Health
Prostate Cancer: Over-Testing and Over-Treatment

From the Brownstone Institute
By
The excessive medical response to the Covid pandemic made one thing abundantly clear: Medical consumers really ought to do their own research into the health issues that impact them. Furthermore, it is no longer enough simply to seek out a “second opinion” or even a “third opinion” from doctors. They may well all be misinformed or biased. Furthermore, this problem appears to predate the Covid phenomenon.
A striking example of that can be found in the recent history of prostate cancer testing and treatment, which, for personal reasons, has become a subject of interest to me. In many ways, it strongly resembles the Covid calamity, where misuse of the PCR test resulted in harming the supposedly Covid-infected with destructive treatments.
Two excellent books on the subject illuminate the issues involved in prostate cancer. One is Invasion of the Prostate Snatchers by Dr. Mark Scholz and Ralph Blum. Dr. Scholtz is executive director of the Prostate Cancer Research Institute in California. The other is The Great Prostate Hoax by Richard Ablin and Ronald Piana. Richard Ablin is a pathologist who invented the PSA test but has become a vociferous critic of its widespread use as a diagnostic tool for prostate cancer.
Mandatory yearly PSA testing at many institutions opened up a gold mine for urologists, who were able to perform lucrative biopsies and prostatectomies on patients who had PSA test numbers above a certain level. However, Ablin has insisted that “routine PSA screening does far more harm to men than good.” Moreover, he maintains that the medical people involved in prostate screening and treatment represent “a self-perpetuating industry that has maimed millions of American men.”
Even during approval hearings for the PSA test, the FDA was well aware of the problems and dangers. For one thing, the test has a 78% false positive rate. An elevated PSA level can be caused by various factors besides cancer, so it is not really a test for prostate cancer. Moreover, a PSA test score can spur frightened men into getting unnecessary biopsies and harmful surgical procedures.
One person who understood the potential dangers of the test well was the chairman of the FDA’s committee, Dr. Harold Markovitz, who decided whether to approve it. He declared, “I’m afraid of this test. If it is approved, it comes out with the imprimatur of the committee…as pointed out, you can’t wash your hands of guilt. . .all this does is threaten a whole lot of men with prostate biopsy…it’s dangerous.”
In the end, the committee did not give unqualified approval to the PSA test but only approved it “with conditions.” However, subsequently, the conditions were ignored.
Nevertheless, the PSA test became celebrated as the route to salvation from prostate cancer. The Postal Service even circulated a stamp promoting yearly PSA tests in 1999. Quite a few people became wealthy and well-known at the Hybritech company, thanks to the Tandem-R PSA test, their most lucrative product.
In those days, the corrupting influence of the pharmaceutical companies on the medical device and drug approval process was already apparent. In an editorial for the Journal of the American Medical Association (quoted in Albin and Piana’s book), Dr. Marcia Angell wrote, “The pharmaceutical industry has gained unprecedented control over the evaluation of its products…there’s mounting evidence that they skew the research they sponsor to make their drugs look better and safer.” She also authored the book The Truth About the Drug Companies: How They Deceive Us and What to Do About It.
A cancer diagnosis often causes great anxiety, but in actuality, prostate cancer develops very slowly compared to other cancers and does not often pose an imminent threat to life. A chart featured in Scholz and Blum’s book compares the average length of life of people whose cancer returns after surgery. In the case of colon cancer, they live on average two more years, but prostate cancer patients live another 18.5 years.
In the overwhelming majority of cases, prostate cancer patients do not die from it but rather from something else, whether they are treated for it or not. In a 2023 article about this issue titled “To Treat or Not to Treat,” the author reports the results of a 15-year study of prostate cancer patients in the New England Journal of Medicine. Only 3% of the men in the study died of prostate cancer, and getting radiation or surgery for it did not seem to offer much statistical benefit over “active surveillance.”
Dr. Scholz confirms this, writing that “studies indicate that these treatments [radiation and surgery] reduce mortality in men with Low and Intermediate-Risk disease by only 1% to 2% and by less than 10% in men with High-Risk disease.”
Nowadays prostate surgery is a dangerous treatment choice, but it is still widely recommended by doctors, especially in Japan. Sadly, it also seems to be unnecessary. One study cited in Ablin and Piana’s book concluded that “PSA mass screening resulted in a huge increase in the number of radical prostatectomies. There is little evidence for improved survival outcomes in the recent years…”
However, a number of urologists urge their patients not to wait to get prostate surgery, threatening them with imminent death if they do not. Ralph Blum, a prostate cancer patient, was told by one urologist, “Without surgery you’ll be dead in two years.” Many will recall that similar death threats were also a common feature of Covid mRNA-injection promotion.
Weighing against prostate surgery are various risks, including death and long-term impairment, since it is a very difficult procedure, even with newer robotic technology. According to Dr. Scholz, about 1 in 600 prostate surgeries result in the death of the patient. Much higher percentages suffer from incontinence (15% to 20%) and impotence after surgery. The psychological impact of these side effects is not a minor problem for many men.
In light of the significant risks and little proven benefit of treatment, Dr. Scholz censures “the urology world’s persistent overtreatment mindset.” Clearly, excessive PSA screening led to inflicting unnecessary suffering on many men. More recently, the Covid phenomenon has been an even more dramatic case of medical overkill.
Ablin and Piana’s book makes an observation that also sheds a harsh light on the Covid medical response: “Isn’t cutting edge innovation that brings new medical technology to the market a good thing for health-care consumers? The answer is yes, but only if new technologies entering the market have proven benefit over the ones they replace.”
That last point especially applies to Japan right now, where people are being urged to receive the next-generation mRNA innovation–the self-amplifying mRNA Covid vaccine. Thankfully, a number seem to be resisting this time.
Business
RFK Jr. planning new restrictions on drug advertising: report

Quick Hit:
The Trump administration is reportedly weighing new restrictions on pharmaceutical ads—an effort long backed by Health Secretary Robert F. Kennedy Jr. Proposals include stricter disclosure rules and ending tax breaks.
Key Details:
-
Two key proposals under review: requiring longer side-effect disclosures in TV ads and removing pharma’s tax deduction for ad spending.
-
In 2024, drug companies spent $10.8 billion on direct-to-consumer ads, with AbbVie and Pfizer among the top spenders.
-
RFK Jr. and HHS officials say the goal is to restore “rigorous oversight” over drug promotions, though no final decision has been made.
Diving Deeper:
According to a Bloomberg report, the Trump administration is advancing plans to rein in direct-to-consumer pharmaceutical advertising—a practice legal only in the U.S. and New Zealand. Rather than banning the ads outright, which could lead to lawsuits, officials are eyeing legal and financial hurdles to limit their spread. These include mandating extended disclosures of side effects and ending tax deductions for ad spending—two measures that could severely limit ad volume, especially on TV.
Health and Human Services Secretary Robert F. Kennedy Jr., who has long called for tougher restrictions on drug marketing, is closely aligned with the effort. “We are exploring ways to restore more rigorous oversight and improve the quality of information presented to American consumers,” said HHS spokesman Andrew Nixon in a written statement. Kennedy himself told Sen. Josh Hawley in May that an announcement on tax policy changes could come “within the next few weeks.”
The ad market at stake is enormous. Drugmakers spent $10.8 billion last year promoting treatments directly to consumers, per data from MediaRadar. AbbVie led the pack, shelling out $2 billion—largely to market its anti-inflammatory drugs Skyrizi and Rinvoq, which alone earned the company over $5 billion in Q1 of 2025.
AbbVie’s chief commercial officer Jeff Stewart admitted during a May conference that new restrictions could force the company to “pivot,” possibly by shifting marketing toward disease awareness campaigns or digital platforms.
Pharma’s deep roots in broadcast advertising—making up 59% of its ad spend in 2024—suggest the impact could be dramatic. That shift would mark a reversal of policy changes made in 1997, when the FDA relaxed requirements for side-effect disclosures, opening the floodgates for modern TV drug commercials.
Supporters of stricter oversight argue that U.S. drug consumption is inflated because of these ads, while critics warn of economic consequences. Jim Potter of the Coalition for Healthcare Communication noted that reinstating tougher ad rules could make broadcast placements “impractical.” Harvard professor Meredith Rosenthal agreed, adding that while ads sometimes encourage patients to seek care, they can also push costly brand-name drugs over generics.
Beyond disclosure rules, the administration is considering changes to the tax code—specifically eliminating the industry’s ability to write off advertising as a business expense. This idea was floated during talks over Trump’s original tax reform but was ultimately dropped from the final bill.
Alberta
Alberta pro-life group says health officials admit many babies are left to die after failed abortions

From LifeSiteNews
Alberta’s abortion policy allows babies to be killed with an ‘induced cardiac arrest’ before a late-term abortion and left to die without medical care if they survive.
A Canadian provincial pro-life advocacy group says health officials have admitted that many babies in the province of Alberta are indeed born alive after abortions and then left to die, and because of this are they are calling upon the province’s health minister to put an end to the practice.
Official data from the Canadian Institute for Health Information (CIHI), which is the federal agency in charge of reporting the nation’s health data, shows that in Alberta in 2023-2024, there were 133 late-term abortions. Of these, 28 babies were born alive after the abortion and left to die.
As noted by Prolife Alberta’s President Murray Ruhl in a recent email, this means the reality in the province is that “some of these babies are born alive… and left to die.”
“Babies born alive after failed late-term abortions are quietly abandoned—left without medical help, comfort, or even a chance to survive,” noted Ruhl.
This fact was brought to light in a recent opinion piece published in the Western Standard by Richard Dur, who serves as the executive director of Prolife Alberta.
Ruhl observed that Dur’s opinion piece has “got the attention of both Alberta Health Services (AHS) and Acute Care Alberta (ACA),” whom he said “confirmed many of the practices we exposed.”
Alberta’s policy when it comes to an abortion committed on a baby older than 21 weeks allows that all babies are killed before being born, however this does not always happen.
“In some circumstances… the patient and health practitioner may consider the option of induced fetal cardiac arrest prior to initiating the termination procedures,” notes Alberta Health Services’ Termination of Pregnancy, PS-92 (PS-92, Section 6.4).
Ruhl noted that, in Alberta, before an “abortion begins, they stop the baby’s heart. On purpose. Why? Because they don’t want a live birth. But sometimes—the child survives. And what then?”
When it comes to the same policy for babies older that 21 weeks, the policy states, “For terminations after 21 weeks and zero (0) days there must be careful consideration and documentation concerning a Do Not Resuscitate order in anticipation of a possible live birth.” (PS-92, Section 6.4).”
Ruhl observed that the reality is, “They plan in advance not to save her—even if she’s born alive.”
If the baby is born alive, the policy states, “Comfort measures and palliative care should be provided.” (PS-92, Section 6.4).
This means, however, that there is no oxygen given, no NICU, “no medical care,” noted Ruhl.
“Their policies call this ‘palliative care.’ We call it what it is: abandonment. Newborns deserve care—not a death sentence,” he noted.
As reported by LifeSiteNews recently, a total of 150 babies were born after botched abortions in 2023-2024 in Canada. However, it’s not known how many survived.
Only two federal parties in Canada, the People’s Party of Canada, and the Christian Heritage Party, have openly called for a ban on late abortions in the nation.
Policy now under ‘revision’ says Alberta Health Services
Ruhl said that the province’s policies are now “under revision,” according to AHS.
Because of this, Ruhl noted that now is the time to act and let the province’s Health Minister, Adriana LaGrange, who happens to be pro-life, act and “demand” from her real “action to protect babies born alive after failed abortions.”
The group is asking the province to do as follows below:
- Amend the AHS Termination of Pregnancy policy to require resuscitative care for any baby born with signs of life, regardless of how the birth occurred.
- Require that these newborns receive the same level of care as any other premature baby. Newborns deserve care—not a death sentence.
- Recognize that these babies have a future—there is a literal waiting list of hundreds of families ready to adopt them. There is a home for every one of them.
While many in the cabinet and caucus of Alberta Premier Danielle Smith’s United Conservative government are pro-life, she has still been relatively soft on social issues of importance to conservatives, such as abortion.
-
Business1 day ago
Canada’s critical minerals are key to negotiating with Trump
-
Alberta2 days ago
Central Alberta MP resigns to give Conservative leader Pierre Poilievre a chance to regain a seat in Parliament
-
Business18 hours ago
RFK Jr. planning new restrictions on drug advertising: report
-
conflict1 day ago
Trump dismisses US intelligence that Iran wasn’t pursuing nuclear bomb before Israeli attack
-
Alberta1 day ago
Unified message for Ottawa: Premier Danielle Smith and Premier Scott Moe call for change to federal policies
-
Daily Caller2 days ago
‘Not Held Hostage Anymore’: Economist Explains How America Benefits If Trump Gets Oil And Gas Expansion
-
Economy1 day ago
Ottawa’s muddy energy policy leaves more questions than answers
-
Alberta2 days ago
Alberta pro-life group says health officials admit many babies are left to die after failed abortions